0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%

Vertex Pharmaceuticals Inc

Healthcare US VRTX

391.8049USD
-55.6951(12.45%)

Last update at 2024-12-19T18:54:00Z

Day Range

377.85403.60
LowHigh

52 Week Range

320.01457.66
LowHigh

Fundamentals

  • Previous Close 447.50
  • Market Cap115318.72M
  • Volume5450324
  • P/E Ratio29.67
  • Dividend Yield-%
  • EBITDA4583.70M
  • Revenue TTM10185.00M
  • Revenue Per Share TTM39.49
  • Gross Profit TTM 5323.10M
  • Diluted EPS TTM15.06

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 4232.40M 2730.40M 3116.80M 1394.92M 600.24M
Minority interest - - 0.00000M 0.00000M -9.79300M
Net income 3322.00M 2342.10M 2711.65M 1176.81M 2096.90M
Selling general administrative 887.20M 840.10M 770.46M 658.50M 557.62M
Selling and marketing expenses - - - - -
Gross profit 7850.40M 6670.20M 5469.38M 3615.06M 2638.06M
Reconciled depreciation 148.30M 125.60M 109.52M 106.94M 72.42M
Ebit 4307.40M 2782.10M 2856.29M 1197.57M 590.76M
Ebitda 4345.20M 2788.80M 3188.05M 1457.88M 663.18M
Depreciation and amortization 37.80M 6.70M 331.76M 260.31M 72.42M
Non operating income net other -20.20000M 9.80M 318.66M 255.85M -0.79000M
Operating income 4307.40M 2782.10M 2856.29M 1197.57M 635.15M
Other operating expenses 4565.30M 4795.40M 3336.29M 2960.80M 2383.63M
Interest expense 54.80M 61.50M 58.15M 58.50M 34.12M
Tax provision 910.40M 388.30M 405.15M 218.11M -1486.86200M
Interest income 144.60M 4.90M 22.24M 63.68M 33.50M
Net interest income 89.80M -56.60000M -35.91200M 5.18M -34.11900M
Extraordinary items - - - - 1560.00M
Non recurring 115.50M - - - 28.82M
Other items - - - - -
Income tax expense 910.40M 388.30M 405.15M 218.11M -1486.86200M
Total revenue 8930.70M 7574.40M 6205.68M 4162.82M 3047.60M
Total operating expenses 3485.00M 3891.20M 2599.99M 2413.04M 1974.09M
Cost of revenue 1080.30M 904.20M 736.30M 547.76M 409.54M
Total other income expense net -75.00000M -51.70000M 260.51M 197.35M -29.60600M
Discontinued operations - - - - -
Net income from continuing ops 3322.00M 2342.10M 2711.65M 1176.81M 2087.10M
Net income applicable to common shares 3322.00M 2342.10M 2711.65M 1176.81M 2096.90M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 22730.20M 18150.90M 13432.50M 11751.81M 8318.47M
Intangible assets 839.90M 603.60M 400.00M 400.00M 400.00M
Earning assets - - - - -
Other current assets 620.50M 74.40M 187.20M 308.35M 213.51M
Total liab 5149.80M 4238.20M 3332.50M 3064.99M 2233.22M
Total stockholder equity 17580.40M 13912.70M 10100.00M 8686.82M 6085.24M
Deferred long term liab - - - - -
Other current liab 2928.50M 1877.70M 1460.00M 1171.02M 1024.29M
Common stock 2.60M 2.60M 2.50M 2.60M 2.59M
Capital stock 2.60M 2.60M 2.50M 2.60M 2.59M
Retained earnings 10142.40M 6522.80M 3200.80M 858.67M -1852.97800M
Other liab - 685.80M 902.20M 923.41M 275.53M
Good will 1088.00M 1088.00M 1402.20M 1402.16M 1402.16M
Other assets - 1422.70M 986.90M 587.03M 1199.40M
Cash 10372.30M 10504.00M 6795.00M 5988.19M 3109.32M
Cash and equivalents - - - - -
Total current liabilities 3547.40M 2430.60M 1873.60M 1560.11M 1204.52M
Current deferred revenue 170.30M 159.60M 171.70M 191.52M 62.33M
Net debt -9563.90000M -9943.00000M -6238.30000M -5406.71100M -2531.95100M
Short term debt 83.70M 89.40M 46.90M 42.43M 30.29M
Short long term debt - - - - -
Short long term debt total 808.40M 561.00M 556.70M 581.48M 577.37M
Other stockholder equity 7449.70M 7386.50M 6880.80M 7894.03M 7937.61M
Property plant equipment - 1455.80M 1094.10M 958.53M 833.28M
Total current assets 14144.20M 12681.30M 9014.80M 7825.03M 4609.31M
Long term investments 2497.80M - - - 60.80M
Net tangible assets - 12221.10M 8697.80M 7284.66M 4683.09M
Short term investments 849.20M 274.50M 729.90M 670.71M 698.97M
Net receivables 1563.40M 1442.20M 1136.80M 885.35M 633.52M
Long term debt - - - - -
Inventory 738.80M 460.60M 353.10M 280.78M 167.50M
Accounts payable 364.90M 303.90M 195.00M 155.14M 87.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -14.30000M 0.80M 15.90M -68.48000M -1.97300M
Additional paid in capital - - - - -
Common stock total equity - 2.60M 2.50M 2.60M 2.59M
Preferred stock total equity - - - - -
Retained earnings total equity - 6522.80M 3200.80M 858.67M -1852.97800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 796.70M 1422.70M 986.90M 683.31M 371.10M
Deferred long term asset charges - - - - -
Non current assets total 8586.00M 5469.60M 4417.70M 3926.78M 3709.15M
Capital lease obligations 808.40M 471.60M 556.70M 581.48M 538.58M
Long term debt total - - - 539.04M 538.58M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -2079.60000M 227.30M -28.90000M 378.51M 33.66M
Change to liabilities - 1162.20M 354.10M 598.57M 188.09M
Total cashflows from investing activities - -321.10000M -340.90000M 99.39M -1235.31800M
Net borrowings - -85.50000M -24.40000M -29.02400M -35.00500M
Total cash from financing activities -562.20000M -67.70000M -1478.00000M -505.28100M 126.77M
Change to operating activities - 715.00M 230.40M 249.73M 246.32M
Net income 3619.60M 3322.00M 2342.10M 2711.65M 1176.81M
Change in cash -139.70000M 3711.90M 811.20M 2868.16M 462.43M
Begin period cash flow 10512.00M 6800.10M 5988.90M 3120.68M 2658.25M
End period cash flow 10372.30M 10512.00M 6800.10M 5988.85M 3120.68M
Total cash from operating activities 3537.30M 4129.90M 2643.50M 3253.51M 1569.33M
Issuance of capital stock - - - - 343.24M
Depreciation 181.30M 148.30M 125.60M 109.52M 106.94M
Other cashflows from investing activities - -343.70000M -77.00000M -19.32700M -1193.53100M
Dividends paid - - 102.00M 264.95M 10.05M
Change to inventory -322.90000M -136.40000M -92.80000M -132.01400M -64.04700M
Change to account receivables -84.10000M -358.60000M -274.70000M -223.44400M -225.58700M
Sale purchase of stock -427.60000M -172.00000M -1561.30000M -739.40700M -192.01500M
Other cashflows from financing activities -224.30000M 3.50M 130.30M 276.40M 24.77M
Change to netincome - 445.60M 452.70M 521.39M 381.89M
Capital expenditures 258.40M 204.70M 235.00M 259.80M 75.45M
Change receivables - -358.60000M -274.70000M -223.44400M -225.58700M
Cash flows other operating - -453.20000M -263.50000M -332.15800M 5.23M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 3741.10M 824.60M 2847.61M 460.79M
Change in working capital -265.70000M 340.80M -105.20000M -54.45400M -66.10100M
Stock based compensation 581.20M 491.30M 441.40M 429.46M 360.49M
Other non cash items -42.60000M 103.40M -5.80000M -220.00500M -176.19600M
Free cash flow 3278.90M 3925.20M 2408.50M 2993.70M 1493.88M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VRTX
Vertex Pharmaceuticals Inc
-55.6951 12.45% 391.80 29.67 24.33 10.38 5.83 9.33 20.00
NVO
Novo Nordisk A/S
-2.26 2.13% 103.70 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-1.68 1.57% 105.12 41.06 31.25 2.08 33.11 2.11 4.70
REGN
Regeneron Pharmaceuticals Inc
-4.445 0.62% 710.17 29.07 20.12 7.57 3.82 6.95 19.42
CSLLY
CSL Ltd
-0.54 0.62% 86.46 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Inc

50 Northern Avenue, Boston, MA, United States, 02210

Key Executives

Name Title Year Born
Dr. Jeffrey Marc Leiden M.D., Ph.D. Exec. Chairman 1956
Dr. Reshma Kewalramani FASN, M.D. CEO, Pres & Director 1973
Mr. Charles F. Wagner Jr. Exec. VP & CFO 1968
Mr. Stuart A. Arbuckle B.Sc. Exec. VP & COO 1966
Dr. Ourania Tatsis Ph.D. Exec. VP and Chief Regulatory & Quality Officer 1971
Ms. Kristen C. Ambrose Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services 1977
Dr. David M. Altshuler M.D., Ph.D. Exec. VP of Global Research & Chief Scientific Officer 1965
Mr. Mike Tirozzi SVP and Chief Information & Data Officer NA
Susie Lisa Sr. VP of Investor Relations NA
Mr. Damian W. Wilmot Esq. Sr. VP, Chief Risk and Compliance Officer 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions